LSV Asset Management Purchases 138,119 Shares of Bristol Myers Squibb Company $BMY

LSV Asset Management grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 1.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,269,472 shares of the biopharmaceutical company’s stock after acquiring an additional 138,119 shares during the quarter. Bristol Myers Squibb comprises 0.8% of LSV Asset Management’s holdings, making the stock its 22nd largest holding. LSV Asset Management owned 0.41% of Bristol Myers Squibb worth $372,953,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Bristol Myers Squibb by 1.8% in the second quarter. Vanguard Group Inc. now owns 194,925,206 shares of the biopharmaceutical company’s stock valued at $9,023,088,000 after buying an additional 3,522,202 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Geode Capital Management LLC lifted its position in Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after acquiring an additional 723,459 shares in the last quarter. Norges Bank acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $1,554,154,000. Finally, Ameriprise Financial Inc. boosted its position in shares of Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after buying an additional 432,158 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on BMY shares. Piper Sandler restated an “overweight” rating and set a $66.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 price objective (up previously from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Guggenheim reissued a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Citigroup increased their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Stock Down 1.6%

BMY opened at $59.91 on Thursday. The company has a 50 day moving average of $55.00 and a 200 day moving average of $49.28. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The company has a market cap of $121.96 billion, a PE ratio of 17.37, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The company’s revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.